Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn't mean the company is invulnerable to challenges.

UnitedHealth Group stock (NYSE: UNH) has declined by 7% over the past month. This downturn is attributed to several significant investor concerns, including rising medical costs within its Medicare Advantage plans, ongoing regulatory and legal scrutiny, and margin pressures in the Optum division.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.

Evaluate the expected performance of Aramark (ARMK) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Universal Insurance (UVE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Crexendo (CXDO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LiveOne (LVO) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.

Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.

Baidu's online marketing business is facing a double whammy, with a 15% Q2 decline and a bleak Q3 guide. This is the main story the market is focused on. However, the market is mispricing Baidu as a declining ad business, completely ignoring its rapid and successful transformation into a full-stack AI hyperscaler. Baidu's in-house chip development mirrors Google's and Amazon's, de-risks the business geopolitically, and is already winning billion-RMB contracts.

BlackRock TCP Capital continues to underperform, with a 34.2% share price decline and a 22.2% total return loss over the past year. Despite a high 17.5% dividend yield, TCPC's net investment income and portfolio activity are declining, raising concerns about long-term sustainability. TCPC trades at a historically large 34.56% discount to NAV, reflecting portfolio weakness and negative sentiment in the debt markets.

Nuwellis, Inc. ( NUWE ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Leah McMullen - Director of Communications John Erb - Interim CFO, Interim Principal Financial & Accounting Officer, CEO, President and Chairman Lynn Blake Presentation Operator Good day, everyone, and welcome to today's Nuwellis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today's call will be recorded, and I will be standing by should you need any assistance.

Acurx Pharmaceuticals, Inc. ( ACXP ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Matthew Keller - H.C. Wainwright & Co, LLC, Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Greetings, and welcome to the Acurx Pharmaceuticals Third Quarter 2025 Conference Call and Business Update.

Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago.

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (“Tvardi” or “the Company”) (NASDAQ: TVRD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Geospace Technologies (GEOS) has transformed from a chronic underperformer to a recent stock market winner through strategic diversification and high-profile contracts. GEOS's expansion into smart water infrastructure and border security, alongside its core energy business, has driven strong revenue growth and improved operational efficiency. Despite diversification, GEOS still struggles to achieve sustainable profitability, with only intermittent positive net income and a history of volatile earnings.

Microsoft Corporation delivered strong Q1 results, with top-line growth accelerating and Azure driving robust performance. MSFT's Intelligent Cloud segment saw 28% YoY growth, with Azure and cloud services up 40%, justifying heavy CAPEX investment. Despite slightly mixed Q2 guidance and some margin pressure, demand for AI compute remains strong, supporting continued growth.

Gold remains choppy and range bound as traders assess the impact of the US dollar and global rate expectations. Key levels between $4,150 and $4,200 define near-term action, with the 50-day EMA serving as critical support for this trend overall.

VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rodents may be experts at staying hidden, but in Metro Vancouver, there's a new sleuth on the case. Orkin Canada has launched its professional K9 rodent detection service in the region, using a specially trained rescue dog, Puzzle, to sniff out live rodent activity with unmatched accuracy.